NCT03793088

Brief Summary

XCELSIOR is a non-interventional data registry. Information about treatments, treatment decisions and rationale, and patient outcomes including safety and effectiveness of anti-cancer therapy and associated supportive care will be collected for analysis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 2, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 4, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

February 7, 2019

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2026

Completed
Last Updated

February 3, 2023

Status Verified

January 1, 2023

Enrollment Period

4.9 years

First QC Date

January 2, 2019

Last Update Submit

January 31, 2023

Conditions

Oncology

Keywords

GlioblastomaGliomaPancreatic Adenocarcinoma

Outcome Measures

Primary Outcomes (2)

  • Progression Free Survival (PFS)

    5 Years

  • Overall Survival (OS)

    5 years

Eligibility Criteria

Age0 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study will initially include up to 10,000 adult and pediatric patients with recalcitrant or advanced cancers.

You may qualify if:

  • Both male and female patients with known or suspected recalcitrant or advanced cancer are eligible to enroll through the Cancer Commons Website
  • Patients with any performance status, comorbidity or disease severity are eligible
  • Patients or their legally-authorized representative must be willing and able to provide written, informed consent (and assent, if applicable)

You may not qualify if:

  • Patients must be a resident of or receiving care within the United States or US territories.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cancer Commons

Los Altos, California, 94022, United States

RECRUITING

Related Links

MeSH Terms

Conditions

NeoplasmsGlioblastomaGlioma

Condition Hierarchy (Ancestors)

AstrocytomaNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Study Officials

  • Mark Shapiro

    xCures / Cancer Commons

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Bryan J Federowicz

CONTACT

707-641-4475bfederowicz@xcures.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 2, 2019

First Posted

January 4, 2019

Study Start

February 7, 2019

Primary Completion

January 1, 2024

Study Completion

January 1, 2026

Last Updated

February 3, 2023

Record last verified: 2023-01

Locations

US(1)